Ani Pharmaceuticals (ANIP) Cash & Current Investments (2010 - 2026)

Ani Pharmaceuticals has disclosed Cash & Current Investments across 17 years of filings, most recently posting $311.2 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $311.2 million, up 107.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $311.2 million (up 107.7% YoY), and the FY2025 annual result was $285.6 million, up 97.12% from the prior year.
• Cash & Current Investments came in at $311.2 million for Q1 2026 at Ani Pharmaceuticals, up from $285.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $311.2 million in Q1 2026 to a low of $53.2 million in Q4 2022.
• The 5-year median for Cash & Current Investments is $161.7 million (2023), against an average of $170.2 million.
• Across the five-year window, Cash & Current Investments tumbled 49.45% in 2022 and soared 315.38% in 2023, its largest moves.
• Ani Pharmaceuticals' Cash & Current Investments stood at $53.2 million in 2022, then surged by 315.38% to $221.1 million in 2023, then tumbled by 34.47% to $144.9 million in 2024, then surged by 97.12% to $285.6 million in 2025, then grew by 8.96% to $311.2 million in 2026.
• The last three Cash & Current Investments figures came in at $311.2 million (Q1 2026), $285.6 million (Q4 2025), and $262.6 million (Q3 2025), per Business Quant data.